Activated Charcoal Apple Atlantic Cod Atlantic Sal
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Activated Charcoal Apple Atlantic Cod Atlantic Sal
- Multi-Ingredient Complex Mixture: Insufficient Data for Drug Repurposing Evaluation
Multi-Ingredient Complex Mixture: Insufficient Data for Drug Repurposing Evaluation
One-Sentence Summary
This candidate entry contains a complex mixture of 55+ ingredients spanning foods, allergens, homeopathic substances, and pharmacological agents (e.g., cortisone acetate, histamine dihydrochloride, hyaluronidase), and cannot be treated as a single drug entity for repurposing analysis. The TxGNN model returned no predicted indications, and the entry carries no US regulatory approvals, no DrugBank ID, and no mechanism of action data — making a standard repurposing evaluation impossible at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established (no regulatory approval found) |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only, but no predictions were generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
TxGNN operates by mapping a drug’s INN to a DrugBank node, then traversing the knowledge graph to score candidate disease relationships. This candidate failed at the first step for two compounding reasons:
1. No resolvable single INN. The entry contains 55 distinct substances — ranging from common foods (apple, banana, wheat) and seafood (Atlantic cod, Pacific oyster) to homeopathic botanicals (Gelsemium sempervirens root, Pulsatilla pratensis, Lycopodium clavatum spore) and pharmacologically active agents (cortisone acetate, serotonin hydrochloride, hyaluronidase, interferon γ porcine recombinant). A knowledge graph prediction model requires a singular, identifiable drug node; a heterogeneous 55-component list cannot be anchored to any single DrugBank entry.
2. No DrugBank ID available. The DrugBank query returned one result but no matching ID was assigned (drugbank_id: null), confirming the mixture could not be mapped to a standard pharmacological entity.
Without a valid drug node, TxGNN has no traversal starting point and correctly returns an empty prediction list. This is expected behavior, not a model failure.
US Market Information
No regulatory licenses were found in the US database for this entry (TFDA query returned 0 results, total_licenses = 0).
Safety Considerations
Please refer to the package insert for safety information.
Note: Some individual components carry known pharmacological activity that warrants attention regardless of the mixture’s overall regulatory status:
- Cortisone acetate — a corticosteroid with immunosuppressive effects and well-characterized adrenal suppression risk
- Histamine dihydrochloride — a vasoactive amine; systemic exposure requires careful dose control
- Hyaluronidase — a spreading factor enzyme; may potentiate absorption of co-administered agents
- Interferon γ (porcine recombinant) — cytokine with immunomodulatory effects; potential for systemic inflammatory reactions
- Serotonin hydrochloride — serotonergic agonist; interaction risk with SSRIs/MAOIs
These components individually have safety profiles that would require evaluation if the product were to be submitted for regulatory review.
Conclusion and Next Steps
Decision: Hold
Rationale: This entry does not represent a single drug and cannot be evaluated under the standard TxGNN drug repurposing framework. TxGNN produced zero predictions because no valid drug identity could be resolved from the 55-ingredient list.
To proceed, the following is needed:
- Clarify the product identity: Determine whether this is a registered homeopathic product, an allergy immunotherapy panel, a diagnostic reagent kit, or another product category — and retrieve its official product name and regulatory classification.
- Identify the active pharmaceutical ingredient (API): If repurposing evaluation is intended for a specific component (e.g., cortisone acetate or hyaluronidase), submit that single INN as a separate Evidence Pack.
- Obtain DrugBank mapping: Once the API is isolated, resolve its DrugBank ID to enable TxGNN traversal.
- Retrieve package insert: Required to complete DG001 (safety warnings/contraindications) and DG002 (mechanism of action).
- Determine regulatory pathway: If this is a homeopathic combination product, it may fall outside standard NDA/ANDA review scope and require a different evaluation framework.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.